Kudo M - Search Results

1

Ramucirumab in patients with previously treated advanced hepatocellular carcinoma: Impact of liver disease aetiology.

Galle PR, Kudo M, Llovet JM, Finn RS, Karwal M, Pezet D, Kim TY, Yang TS, Lonardi S, Tomasek J, Phelip JM, Touchefeu Y, Koh SJ, Stirnimann G, Liang K, Ogburn KD, Wang C, Abada P, Widau RC, Zhu AX. Galle PR, et al. Among authors: kudo m. Liver Int. 2021 Nov;41(11):2759-2767. doi: 10.1111/liv.14994. Epub 2021 Aug 8. Liver Int. 2021. PMID: 34173317 Free article.

2

Hepatocellular carcinoma 2009 and beyond: from the surveillance to molecular targeted therapy.

Kudo M. Kudo M. Oncology. 2008;75 Suppl 1:1-12. doi: 10.1159/000181865. Epub 2008 Dec 17. Oncology. 2008. PMID: 19092266 Review.

3

Impact of interferon therapy after curative treatment of hepatocellular carcinoma.

Kudo M. Kudo M. Oncology. 2008;75 Suppl 1:30-41. doi: 10.1159/000173422. Epub 2008 Dec 17. Oncology. 2008. PMID: 19092270

4

Validation of a new prognostic staging system for hepatocellular carcinoma: a comparison of the biomarker-combined Japan Integrated Staging Score, the conventional Japan Integrated Staging Score and the BALAD Score.

Kitai S, Kudo M, Minami Y, Haji S, Osaki Y, Oka H, Seki T, Kasugai H, Sasaki Y, Matsunaga T. Kitai S, et al. Among authors: kudo m. Oncology. 2008;75 Suppl 1:83-90. doi: 10.1159/000173428. Epub 2008 Dec 17. Oncology. 2008. PMID: 19092276

5

PIVKA-II is the best prognostic predictor in patients with hepatocellular carcinoma after radiofrequency ablation therapy.

Takahashi S, Kudo M, Chung H, Inoue T, Ishikawa E, Kitai S, Tatsumi C, Ueda T, Nagai T, Minami Y, Ueshima K. Takahashi S, et al. Among authors: kudo m. Oncology. 2008;75 Suppl 1:91-8. doi: 10.1159/000173429. Epub 2008 Dec 17. Oncology. 2008. PMID: 19092277

6

Combination therapy with S-1 and pegylated interferon alpha for advanced hepatocellular carcinoma.

Ueshima K, Kudo M, Nagai T, Tatsumi C, Ueda T, Takahashi S, Hatanaka K, Kitai S, Ishikawa E, Inoue T, Hagiwara S, Minami Y, Chung H. Ueshima K, et al. Among authors: kudo m. Oncology. 2008;75 Suppl 1:106-13. doi: 10.1159/000173431. Epub 2008 Dec 17. Oncology. 2008. PMID: 19092279

7

Identification and characterization of IgG4-associated autoimmune hepatitis.

Chung H, Watanabe T, Kudo M, Maenishi O, Wakatsuki Y, Chiba T. Chung H, et al. Among authors: kudo m. Liver Int. 2010 Feb;30(2):222-31. doi: 10.1111/j.1478-3231.2009.02092.x. Epub 2009 Jul 24. Liver Int. 2010. PMID: 19650840

8

[Molecular targeted therapy for advanced hepatocellular carcinoma].

Kudo M. Kudo M. Nihon Shokakibyo Gakkai Zasshi. 2009 Dec;106(12):1712-26. Nihon Shokakibyo Gakkai Zasshi. 2009. PMID: 19966513 Review. Japanese. No abstract available.

9

Radiofrequency ablation guided by contrast harmonic sonography using perfluorocarbon microbubbles (Sonazoid) for hepatic malignancies: an initial experience.

Minami Y, Kudo M, Hatanaka K, Kitai S, Inoue T, Hagiwara S, Chung H, Ueshima K. Minami Y, et al. Among authors: kudo m. Liver Int. 2010 May;30(5):759-64. doi: 10.1111/j.1478-3231.2010.02226.x. Liver Int. 2010. PMID: 20456042

10

Current status of molecularly targeted therapy for hepatocellular carcinoma: clinical practice.

Kudo M. Kudo M. Int J Clin Oncol. 2010 Jun;15(3):242-55. doi: 10.1007/s10147-010-0089-y. Epub 2010 May 28. Int J Clin Oncol. 2010. PMID: 20509038 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

2,479 results

Search Page